Opioid-Induced Constipation in Oncological Patients: New Strategies of Management

被引:0
作者
Ricard Mesía
Juan Antonio Virizuela Echaburu
Jose Gómez
Tamara Sauri
Gloria Serrano
Eduardo Pujol
机构
[1] Instituto Catalán de Oncología,Servicio de Oncología Médica
[2] Hospital General Universitario Virgen Macarena,Servicio de Oncología Médica
[3] Hospital la Fe,undefined
[4] Hospital Clinic de Barcelona,undefined
[5] Hospital Infanta Leonor,undefined
[6] Hospital Clínico Lozano Blesa,undefined
来源
Current Treatment Options in Oncology | 2019年 / 20卷
关键词
Cancer; Opioid-induced constipation; Opioid analgesics; Pain; Naloxegol; Laxatives;
D O I
暂无
中图分类号
学科分类号
摘要
Cancer-associated pain has traditionally been treated with opioid analgesics, often in escalating doses. Opioid-induced constipation (OIC) is a common problem associated with chronic use of opioid analgesics. Typical treatment strategies to alleviate constipation are based on dietary changes, exercise, and laxatives. However, laxatives have a nonspecific action and do not target underlying mechanisms of OIC. This article will review prevalent, clinical presentation and recommendations for the treatment of OIC. An independent literature search was carried out by the authors. We reviewed the literature for randomized controlled trials that studied the efficacy of laxatives, naloxone, and naloxegol in treating OIC. Newer strategies addressing the causal pathophysiology of OIC are needed for a more effective assessment and management of OIC. Finally, traditional recommended therapies are appraised and compared with the latest pharmacological developments. Future research should address whether naloxegol is more efficacious by its comparison directly with first-line treatments, including laxatives.
引用
收藏
相关论文
共 287 条
[41]  
Apolone G(2019)Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting mu-opioid receptor antagonist Drug Metab Pharmacokinet 34 126-1053
[42]  
van den Beuken-van Everdingen MHHL(2019)A meta-analysis of naldemedine for the treatment of opioid-induced constipation Expert Rev Clin Pharmacol 12 121-208
[43]  
Joosten EA(2019)Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies J Pain Res 12 127-291
[44]  
Tjan-Heijnen VC(2019)Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects Xenobiotica 49 1044-1550
[45]  
Janssen DJ(2017)Methylnaltrexone versus naloxone for opioid-induced constipation in the medical intensive care unit Ann Pharmacother 51 203-2396
[46]  
Portenoy RK(2007)Evaluation of single oral doses of NKTR118 (PEG-Naloxol) as a peripheral opioid antagonist (POA): a double-blind placebo-controlled study in healthy male subjects J Clin Pharmacol 47 1210-480
[47]  
Ganzer H(2017)Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation Journal of Pharmacology and Experimental Therapeutics 361 280-1883
[48]  
Touger-Decker R(2013)A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation Pain 154 1542-107
[49]  
Byham-Gray L(2014)Naloxegol for opioid-induced constipation in patients with noncancer pain N Engl J Med 370 2387-1266
[50]  
Murphy BA(2015)Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response United European Gastroenterol J 3 471-1135